In This Article:
Multiple acquisitions to drive significant growth of customer base
LEHI, UT / ACCESSWIRE / February 14, 2020 / Frelii, Inc. (OTC PINK:FRLI) ("Frelii" or the "Company"), a biotechnology company working to commercialize its patent-pending DNA gene sequencing artificial intelligence technology, announced today an update regarding its previously announced revenue sharing agreement with GATC Canna Corp. ("GATC").
GATC recently announced the closing of two diverse acquisitions, detailed below, that are expected to significantly increase the Frelii customer base while generating ongoing revenue as per the terms of its revenue sharing agreement.
GATC's acquisitions;
-
GATC secured a 51% controlling interest in Dvija Health Sciences Corp (DHSC). Contracted with DeckerMed, a leading Continuing Medical Education (CME) provider in North America, DHSC will create up to 25 modules for doctor training and certification in the medicine of cannabis. GATC Canna will also white label modules on the DeckerMed e-Learning Platform under the GATC Canna brand, marketing to over 100,000 medical professionals in all areas of medicine. This agreement formalizes several important revenue streams for GATC Canna; revenue from sales of DeckerMed's CME modules followed by the co-branded modules, as well as GATC Canna subscriptions paid by physicians and other medical professionals who will be introduced to GATC Canna through the CME modules.
-
Through a share exchange agreement GATC secured a 100% interest in Mandala MD LLC, a telemedicine group based in Quad Cities area of Iowa and Illinois that specializes in cannabis-based medicines. The transaction brings considerable medical, technical and marketing expertise to GATC Canna, and is a key component of its vertically integrated DNA-based medical cannabis platform. Mandala MD will exist as a subsidiary of GATC Canna Corp. Prior to this acquisition, Mandala MD was given a valuation of $50 million during an equity round of funding.
Frelii CEO, Ian Jenkins, stated, "In structuring our growth strategy we believed in our technology and its ability to scale through various licensing partners such as GATC Canna. With the addition of GATC's new interests and assets, we anticipate the subsequent flow-through growth across the board to surpass our previous expectations. We look forward to continuing the progression of our revenue sharing agreements in support of our commitment to building long-term shareholder value."
About Frelii
Frelii Inc. is a biotechnology company utilizing human DNA gene sequencing and artificial intelligence (AI) to assess more than 3.2 billion markers on the human genome. The resulting data provides valuable insight into an individual's DNA which are aligned and leveraged against its AI as a means of creating a robust data platform for use by a variety of sectors, including Health & Wellness, Healthcare, Medical Cannabis and Pharmaceutical.